You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMinaprine
Accession NumberDB00805  (APRD00735)
TypeSmall Molecule
GroupsApproved
DescriptionMinaprine is a psychotropic drug which has proved to be effective in the treatment of various depressive states. Like most antidepressants minaprine antagonizes behavioral despair. Minaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain.
Structure
Thumb
Synonyms
4-(2-((4-Methyl-6-phenyl-3-pyridazinyl)amino)ethyl)morpholine
4-Methyl-3-(2-morpholinoethylamino)-6-phenylpyridazin
Minaprina
Minaprinum
N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CantorSanofi-Aventis
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Minaprine Dihydrochloride
25953-17-7
Thumb
  • InChI Key: GNUCGROXDZMCJI-UHFFFAOYSA-N
  • Monoisotopic Mass: 370.132716824
  • Average Mass: 371.305
DBSALT000305
Categories
UNII00U7GX0NLM
CAS number25905-77-5
WeightAverage: 298.3828
Monoisotopic: 298.179361346
Chemical FormulaC17H22N4O
InChI KeyInChIKey=LDMWSLGGVTVJPG-UHFFFAOYSA-N
InChI
InChI=1S/C17H22N4O/c1-14-13-16(15-5-3-2-4-6-15)19-20-17(14)18-7-8-21-9-11-22-12-10-21/h2-6,13H,7-12H2,1H3,(H,18,20)
IUPAC Name
4-methyl-N-[2-(morpholin-4-yl)ethyl]-6-phenylpyridazin-3-amine
SMILES
CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpyridazines. These are organic compounds containing a pyridazine ring substituted by a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyridazines and derivatives
Direct ParentPhenylpyridazines
Alternative Parents
Substituents
  • Phenylpyridazine
  • Secondary aliphatic/aromatic amine
  • Aminopyridazine
  • Imidolactam
  • Benzenoid
  • Oxazinane
  • Morpholine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Azacycle
  • Secondary amine
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of depression
PharmacodynamicsMinaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain. Similar to other antidepressant treatments, minaprine attenuates the beta-adrenergic receptor function. Studies have also shown that minaprine improves memory consolidation and that repeated drug administration leads to potentiation of this effect. Moreover, the effects of minaprine on memory consolidation are related to its dopaminergic action.
Mechanism of actionMinaprine binds to serotonin type 2 receptors and to dopamine D1 and D2 type receptors. It also binds to the serotonin reuptake pump. Therefore, minaprine blocks the reuptake of both dopamine and serotonin. It is also, to a slight degree, cholinomimetic. Thus it may exhibit both mood-brightening and nootropic properties. It also acts as a reversible inhibitor of MAO-A (RIMA).It has also been found to inhibit acetylcholinesterase.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic. Cytochrome P4502D is responsible for the 4-hydroxylation of minaprine to 4-hydroxyminaprine.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9843
Caco-2 permeable+0.5161
P-glycoprotein substrateSubstrate0.7122
P-glycoprotein inhibitor IInhibitor0.5884
P-glycoprotein inhibitor IINon-inhibitor0.6707
Renal organic cation transporterNon-inhibitor0.5938
CYP450 2C9 substrateNon-substrate0.8053
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.5794
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.576
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5741
Ames testNon AMES toxic0.7642
CarcinogenicityNon-carcinogens0.7084
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity2.4667 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7911
hERG inhibition (predictor II)Inhibitor0.6866
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point122 °CPhysProp
water solubility2360 mg/LNot Available
logP2.03HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0701 mg/mLALOGPS
logP2.15ALOGPS
logP2.19ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)19.25ChemAxon
pKa (Strongest Basic)6.28ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area50.28 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity91.17 m3·mol-1ChemAxon
Polarizability33.82 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN06AX07
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineMinaprine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineMinaprine may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Minaprine.
AbirateroneThe metabolism of Minaprine can be decreased when combined with Abiraterone.
AcarboseMinaprine may increase the hypoglycemic activities of Acarbose.
AcebutololMinaprine may increase the bradycardic activities of Acebutolol.
AcetylcholineThe risk or severity of adverse effects can be increased when Minaprine is combined with Acetylcholine.
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Minaprine.
AlbiglutideMinaprine may increase the hypoglycemic activities of Albiglutide.
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Minaprine.
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Minaprine.
AliskirenMinaprine may increase the hypotensive activities of Aliskiren.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Minaprine.
AlogliptinMinaprine may increase the hypoglycemic activities of Alogliptin.
AlprenololMinaprine may increase the bradycardic activities of Alprenolol.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Minaprine.
AmbrisentanMinaprine may increase the hypotensive activities of Ambrisentan.
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Minaprine.
AmineptineMinaprine may increase the serotonergic activities of Amineptine.
AmiodaroneThe metabolism of Minaprine can be decreased when combined with Amiodarone.
AmitriptylineMinaprine may increase the serotonergic activities of Amitriptyline.
AmlodipineMinaprine may increase the hypotensive activities of Amlodipine.
AmoxapineMinaprine may increase the serotonergic activities of Amoxapine.
AmphetamineMinaprine may increase the hypertensive activities of Amphetamine.
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Minaprine.
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Minaprine.
ApraclonidineThe risk or severity of adverse effects can be increased when Minaprine is combined with Apraclonidine.
ArbutamineThe risk or severity of adverse effects can be increased when Minaprine is combined with Arbutamine.
ArecolineThe risk or severity of adverse effects can be increased when Minaprine is combined with Arecoline.
ArformoterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Arformoterol.
ArotinololMinaprine may increase the bradycardic activities of Arotinolol.
ArtemetherThe metabolism of Minaprine can be decreased when combined with Artemether.
AtenololMinaprine may increase the bradycardic activities of Atenolol.
AtomoxetineMinaprine may increase the central neurotoxic activities of Atomoxetine.
AtomoxetineThe metabolism of Minaprine can be decreased when combined with Atomoxetine.
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Minaprine.
AtropineMinaprine may increase the hypertensive activities of Atropine.
BambuterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Bambuterol.
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Minaprine.
BefunololMinaprine may increase the bradycardic activities of Befunolol.
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Minaprine.
BenazeprilMinaprine may increase the hypotensive activities of Benazepril.
BendroflumethiazideMinaprine may increase the hypotensive activities of Bendroflumethiazide.
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Minaprine.
BenzphetamineMinaprine may increase the hypertensive activities of Benzphetamine.
BepridilMinaprine may increase the hypotensive activities of Bepridil.
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Minaprine.
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Minaprine.
BetaxololMinaprine may increase the bradycardic activities of Betaxolol.
BetaxololThe metabolism of Minaprine can be decreased when combined with Betaxolol.
BethanecholThe risk or severity of adverse effects can be increased when Minaprine is combined with Bethanechol.
BethanidineMinaprine may increase the hypotensive activities of Bethanidine.
BevantololMinaprine may increase the bradycardic activities of Bevantolol.
BezafibrateThe risk or severity of adverse effects can be increased when Minaprine is combined with Bezafibrate.
BimatoprostMinaprine may increase the hypotensive activities of Bimatoprost.
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Minaprine.
BisoprololMinaprine may increase the bradycardic activities of Bisoprolol.
BopindololMinaprine may increase the bradycardic activities of Bopindolol.
BosentanMinaprine may increase the hypotensive activities of Bosentan.
BretyliumMinaprine may increase the hypotensive activities of Bretylium.
BrimonidineThe risk or severity of adverse effects can be increased when Minaprine is combined with Brimonidine.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Minaprine.
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Minaprine.
BufuralolMinaprine may increase the bradycardic activities of Bufuralol.
BupranololMinaprine may increase the bradycardic activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Minaprine.
BupropionMinaprine may increase the hypertensive activities of Bupropion.
BupropionThe metabolism of Minaprine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Minaprine.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Minaprine.
CanagliflozinMinaprine may increase the hypoglycemic activities of Canagliflozin.
CandesartanMinaprine may increase the hypotensive activities of Candesartan.
CandoxatrilMinaprine may increase the hypotensive activities of Candoxatril.
CaptoprilMinaprine may increase the hypotensive activities of Captopril.
CarbacholThe risk or severity of adverse effects can be increased when Minaprine is combined with Carbachol.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Minaprine.
CarteololMinaprine may increase the bradycardic activities of Carteolol.
CarvedilolMinaprine may increase the bradycardic activities of Carvedilol.
CelecoxibThe metabolism of Minaprine can be decreased when combined with Celecoxib.
CeliprololMinaprine may increase the bradycardic activities of Celiprolol.
CevimelineThe risk or severity of adverse effects can be increased when Minaprine is combined with Cevimeline.
ChloroquineThe metabolism of Minaprine can be decreased when combined with Chloroquine.
ChlorothiazideMinaprine may increase the hypotensive activities of Chlorothiazide.
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Minaprine.
ChlorphentermineMinaprine may increase the hypertensive activities of Chlorphentermine.
ChlorpromazineThe metabolism of Minaprine can be decreased when combined with Chlorpromazine.
ChlorpropamideMinaprine may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneMinaprine may increase the hypotensive activities of Chlorthalidone.
CholecalciferolThe metabolism of Minaprine can be decreased when combined with Cholecalciferol.
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Minaprine.
CilazaprilMinaprine may increase the hypotensive activities of Cilazapril.
CimetidineThe metabolism of Minaprine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Minaprine can be decreased when combined with Cinacalcet.
CirazolineMinaprine may increase the hypertensive activities of Cirazoline.
CitalopramMinaprine may increase the serotonergic activities of Citalopram.
CitalopramThe metabolism of Minaprine can be decreased when combined with Citalopram.
ClemastineMinaprine may increase the anticholinergic activities of Clemastine.
ClemastineThe metabolism of Minaprine can be decreased when combined with Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Clenbuterol.
ClobazamThe metabolism of Minaprine can be decreased when combined with Clobazam.
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Minaprine.
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Minaprine.
ClomipramineMinaprine may increase the serotonergic activities of Clomipramine.
ClomipramineThe metabolism of Minaprine can be decreased when combined with Clomipramine.
ClonidineMinaprine may increase the hypotensive activities of Clonidine.
ClotrimazoleThe metabolism of Minaprine can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Minaprine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Minaprine can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Minaprine can be decreased when combined with Cocaine.
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Minaprine.
CryptenamineMinaprine may increase the hypotensive activities of Cryptenamine.
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Minaprine.
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Minaprine.
CyclothiazideMinaprine may increase the hypotensive activities of Cyclothiazide.
CyproheptadineMinaprine may increase the anticholinergic activities of Cyproheptadine.
DapagliflozinMinaprine may increase the hypoglycemic activities of Dapagliflozin.
DapoxetineMinaprine may increase the serotonergic activities of Dapoxetine.
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Minaprine.
DarifenacinThe metabolism of Minaprine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Minaprine can be increased when it is combined with Darunavir.
DebrisoquinMinaprine may increase the hypotensive activities of Debrisoquin.
DehydroepiandrosteroneThe risk or severity of adverse effects can be increased when Dehydroepiandrosterone is combined with Minaprine.
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Minaprine.
DelavirdineThe metabolism of Minaprine can be decreased when combined with Delavirdine.
DeserpidineMinaprine may increase the hypotensive activities of Deserpidine.
DesipramineMinaprine may increase the serotonergic activities of Desipramine.
DesipramineThe metabolism of Minaprine can be decreased when combined with Desipramine.
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Minaprine.
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Minaprine.
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Minaprine.
DesvenlafaxineMinaprine may increase the serotonergic activities of Desvenlafaxine.
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Minaprine.
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Minaprine.
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Minaprine.
DexmethylphenidateMinaprine may increase the hypertensive activities of Dexmethylphenidate.
DextroamphetamineMinaprine may increase the hypertensive activities of Dextroamphetamine.
DextromethorphanMinaprine may increase the serotonergic activities of Dextromethorphan.
DiazoxideMinaprine may increase the hypotensive activities of Diazoxide.
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Minaprine.
DiethylpropionMinaprine may increase the hypertensive activities of Diethylpropion.
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Minaprine.
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Minaprine.
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Minaprine.
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Minaprine.
DiltiazemMinaprine may increase the hypotensive activities of Diltiazem.
DiphenhydramineThe metabolism of Minaprine can be decreased when combined with Diphenhydramine.
DipivefrinThe risk or severity of adverse effects can be increased when Minaprine is combined with Dipivefrin.
DipyridamoleThe therapeutic efficacy of Minaprine can be decreased when used in combination with Dipyridamole.
DisopyramideMinaprine may increase the hypoglycemic activities of Disopyramide.
DobutamineThe risk or severity of adverse effects can be increased when Minaprine is combined with Dobutamine.
DomperidoneThe risk or severity of adverse effects can be increased when Minaprine is combined with Domperidone.
DorzolamideMinaprine may increase the hypotensive activities of Dorzolamide.
DosulepinMinaprine may increase the serotonergic activities of Dosulepin.
DoxapramMinaprine may increase the hypertensive activities of Doxapram.
DoxazosinMinaprine may increase the hypotensive activities of Doxazosin.
DoxepinMinaprine may increase the serotonergic activities of Doxepin.
DoxylamineMinaprine may increase the anticholinergic activities of Doxylamine.
DronedaroneThe metabolism of Minaprine can be decreased when combined with Dronedarone.
DroxidopaThe risk or severity of adverse effects can be increased when Minaprine is combined with Droxidopa.
DulaglutideMinaprine may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe metabolism of Minaprine can be decreased when combined with Duloxetine.
DuloxetineMinaprine may increase the serotonergic activities of Duloxetine.
EfonidipineMinaprine may increase the hypotensive activities of Efonidipine.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Minaprine.
EliglustatThe metabolism of Minaprine can be decreased when combined with Eliglustat.
EmpagliflozinMinaprine may increase the hypoglycemic activities of Empagliflozin.
EnalaprilMinaprine may increase the hypotensive activities of Enalapril.
EnalaprilatMinaprine may increase the hypotensive activities of Enalaprilat.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Minaprine.
EphedraThe risk or severity of adverse effects can be increased when Minaprine is combined with Ephedra.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Minaprine is combined with EPIBATIDINE.
EpinephrineMinaprine may increase the hypertensive activities of Epinephrine.
EpoprostenolMinaprine may increase the hypotensive activities of Epoprostenol.
EprosartanMinaprine may increase the hypotensive activities of Eprosartan.
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Minaprine.
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Minaprine.
ErgotamineMinaprine may increase the hypertensive activities of Ergotamine.
EscitalopramMinaprine may increase the serotonergic activities of Escitalopram.
EsmirtazapineMinaprine may increase the serotonergic activities of Esmirtazapine.
EsmololMinaprine may increase the bradycardic activities of Esmolol.
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Minaprine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Minaprine.
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Minaprine.
EtoperidoneMinaprine may increase the serotonergic activities of Etoperidone.
ExenatideMinaprine may increase the hypoglycemic activities of Exenatide.
FelodipineMinaprine may increase the hypotensive activities of Felodipine.
FenfluramineMinaprine may increase the serotonergic activities of Fenfluramine.
FenoldopamMinaprine may increase the hypotensive activities of Fenoldopam.
FenoterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Fenoterol.
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Minaprine.
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Minaprine.
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Minaprine.
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Minaprine.
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Minaprine.
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Minaprine.
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Minaprine.
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Minaprine.
FluoxetineMinaprine may increase the serotonergic activities of Fluoxetine.
FluoxetineThe metabolism of Minaprine can be decreased when combined with Fluoxetine.
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Minaprine.
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Minaprine.
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Minaprine.
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Minaprine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Minaprine.
FluvoxamineMinaprine may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe metabolism of Minaprine can be decreased when combined with Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Formoterol.
FosinoprilMinaprine may increase the hypotensive activities of Fosinopril.
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Minaprine.
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Minaprine.
GliclazideMinaprine may increase the hypoglycemic activities of Gliclazide.
GlimepirideMinaprine may increase the hypoglycemic activities of Glimepiride.
GlipizideMinaprine may increase the hypoglycemic activities of Glipizide.
GlyburideMinaprine may increase the hypoglycemic activities of Glyburide.
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Minaprine.
GTS-21The risk or severity of adverse effects can be increased when Minaprine is combined with GTS-21.
GuanabenzMinaprine may increase the hypotensive activities of Guanabenz.
GuanadrelMinaprine may increase the hypotensive activities of Guanadrel.
GuanethidineMinaprine may increase the hypotensive activities of Guanethidine.
GuanfacineMinaprine may increase the hypotensive activities of Guanfacine.
HaloperidolThe metabolism of Minaprine can be decreased when combined with Haloperidol.
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Minaprine.
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Minaprine.
HydralazineMinaprine may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideMinaprine may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Minaprine is combined with Hydrocodone.
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Minaprine.
HydroflumethiazideMinaprine may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Minaprine is combined with Hydromorphone.
Hydroxyamphetamine hydrobromideMinaprine may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Minaprine.
ImipramineMinaprine may increase the serotonergic activities of Imipramine.
ImipramineThe metabolism of Minaprine can be decreased when combined with Imipramine.
IndacaterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Indacaterol.
IndalpineMinaprine may increase the serotonergic activities of Indalpine.
IndapamideMinaprine may increase the hypotensive activities of Indapamide.
IndenololMinaprine may increase the bradycardic activities of Indenolol.
IndinavirThe metabolism of Minaprine can be decreased when combined with Indinavir.
IndoraminMinaprine may increase the hypotensive activities of Indoramin.
Insulin AspartMinaprine may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirMinaprine may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineMinaprine may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineMinaprine may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanMinaprine may increase the hypoglycemic activities of Insulin Human.
Insulin LisproMinaprine may increase the hypoglycemic activities of Insulin Lispro.
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Minaprine.
IrbesartanMinaprine may increase the hypotensive activities of Irbesartan.
IsoetarineThe risk or severity of adverse effects can be increased when Minaprine is combined with Isoetarine.
IsomethepteneThe risk or severity of adverse effects can be increased when Minaprine is combined with Isometheptene.
IsoniazidThe metabolism of Minaprine can be decreased when combined with Isoniazid.
IsoprenalineThe risk or severity of adverse effects can be increased when Minaprine is combined with Isoprenaline.
IsradipineMinaprine may increase the hypotensive activities of Isradipine.
KetoconazoleThe metabolism of Minaprine can be decreased when combined with Ketoconazole.
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Minaprine.
LabetalolMinaprine may increase the bradycardic activities of Labetalol.
LacidipineMinaprine may increase the hypotensive activities of Lacidipine.
LanreotideMinaprine may increase the hypoglycemic activities of Lanreotide.
LatanoprostMinaprine may increase the hypotensive activities of Latanoprost.
LercanidipineMinaprine may increase the hypotensive activities of Lercanidipine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Minaprine.
LevomilnacipranMinaprine may increase the serotonergic activities of Levomilnacipran.
LevonordefrinMinaprine may increase the hypertensive activities of Levonordefrin.
LinezolidThe risk or severity of adverse effects can be increased when Minaprine is combined with Linezolid.
LiraglutideMinaprine may increase the hypoglycemic activities of Liraglutide.
LisdexamfetamineMinaprine may increase the hypertensive activities of Lisdexamfetamine.
LisinoprilMinaprine may increase the hypotensive activities of Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Minaprine.
LithiumThe risk or severity of adverse effects can be increased when Minaprine is combined with Lithium.
LobelineThe risk or severity of adverse effects can be increased when Minaprine is combined with Lobeline.
LofexidineMinaprine may increase the hypotensive activities of Lofexidine.
LopinavirThe metabolism of Minaprine can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Minaprine can be decreased when combined with Lorcaserin.
LosartanMinaprine may increase the hypotensive activities of Losartan.
Lu AA21004Minaprine may increase the serotonergic activities of Lu AA21004.
LumefantrineThe metabolism of Minaprine can be decreased when combined with Lumefantrine.
MacitentanMinaprine may increase the hypotensive activities of Macitentan.
ManidipineMinaprine may increase the hypotensive activities of Manidipine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Minaprine.
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Minaprine.
MecaserminMinaprine may increase the hypoglycemic activities of Mecasermin.
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Minaprine.
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Minaprine.
MephentermineMinaprine may increase the hypertensive activities of Mephentermine.
MequitazineMinaprine may increase the anticholinergic activities of Mequitazine.
MetaraminolMinaprine may increase the hypertensive activities of Metaraminol.
MetforminMinaprine may increase the hypoglycemic activities of Metformin.
MethacholineThe risk or severity of adverse effects can be increased when Minaprine is combined with Methacholine.
MethadoneThe risk or severity of adverse effects can be increased when Minaprine is combined with Methadone.
MethadoneThe metabolism of Minaprine can be decreased when combined with Methadone.
MethamphetamineMinaprine may increase the hypertensive activities of Methamphetamine.
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Minaprine.
MethotrimeprazineThe metabolism of Minaprine can be decreased when combined with Methotrimeprazine.
MethoxamineMinaprine may increase the hypertensive activities of Methoxamine.
MethyldopaThe risk or severity of adverse effects can be increased when Minaprine is combined with Methyldopa.
Methylene blueMinaprine may increase the serotonergic activities of Methylene blue.
MethylphenidateMinaprine may increase the hypertensive activities of Methylphenidate.
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Minaprine.
MetipranololMinaprine may increase the hypotensive activities of Metipranolol.
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Minaprine.
MetolazoneMinaprine may increase the hypotensive activities of Metolazone.
MetoprololMinaprine may increase the bradycardic activities of Metoprolol.
MetoprololThe metabolism of Minaprine can be decreased when combined with Metoprolol.
MianserinMinaprine may increase the neurotoxic activities of Mianserin.
MibefradilMinaprine may increase the hypotensive activities of Mibefradil.
MidodrineMinaprine may increase the hypertensive activities of Midodrine.
MifepristoneMinaprine may increase the hypoglycemic activities of Mifepristone.
MiglitolMinaprine may increase the hypoglycemic activities of Miglitol.
MilnacipranMinaprine may increase the serotonergic activities of Milnacipran.
MinoxidilMinaprine may increase the hypotensive activities of Minoxidil.
MirabegronThe metabolism of Minaprine can be decreased when combined with Mirabegron.
MirtazapineMinaprine may increase the central neurotoxic activities of Mirtazapine.
MivacuriumMinaprine may decrease the neuromuscular blocking activities of Mivacurium.
MoclobemideThe risk or severity of adverse effects can be increased when Minaprine is combined with Moclobemide.
MoexiprilMinaprine may increase the hypotensive activities of Moexipril.
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Minaprine.
MorphineThe risk or severity of adverse effects can be increased when Minaprine is combined with Morphine.
MoxonidineMinaprine may increase the hypotensive activities of Moxonidine.
N-butylscopolammonium bromideThe therapeutic efficacy of N-butylscopolammonium bromide can be decreased when used in combination with Minaprine.
NadololMinaprine may increase the bradycardic activities of Nadolol.
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Minaprine.
NateglinideMinaprine may increase the hypoglycemic activities of Nateglinide.
NebivololMinaprine may increase the hypotensive activities of Nebivolol.
NevirapineThe metabolism of Minaprine can be decreased when combined with Nevirapine.
NicardipineMinaprine may increase the hypotensive activities of Nicardipine.
NicardipineThe metabolism of Minaprine can be decreased when combined with Nicardipine.
NicorandilMinaprine may increase the hypotensive activities of Nicorandil.
NicotineThe risk or severity of adverse effects can be increased when Minaprine is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Minaprine is combined with Nicotine bitartrate.
NiguldipineMinaprine may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Minaprine can be decreased when combined with Nilotinib.
NilvadipineMinaprine may increase the hypotensive activities of Nilvadipine.
NimodipineMinaprine may increase the hypotensive activities of Nimodipine.
NisoldipineMinaprine may increase the hypotensive activities of Nisoldipine.
NitrendipineMinaprine may increase the hypotensive activities of Nitrendipine.
NitroprussideMinaprine may increase the hypotensive activities of Nitroprusside.
NorepinephrineMinaprine may increase the hypertensive activities of Norepinephrine.
NortriptylineMinaprine may increase the serotonergic activities of Nortriptyline.
NVA237The therapeutic efficacy of NVA237 can be decreased when used in combination with Minaprine.
OctreotideMinaprine may increase the hypoglycemic activities of Octreotide.
OlanzapineMinaprine may increase the serotonergic activities of Olanzapine.
OlmesartanMinaprine may increase the hypotensive activities of Olmesartan.
OlodaterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Olodaterol.
OmapatrilatMinaprine may increase the hypotensive activities of Omapatrilat.
OrciprenalineThe risk or severity of adverse effects can be increased when Minaprine is combined with Orciprenaline.
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Minaprine.
OxprenololMinaprine may increase the bradycardic activities of Oxprenolol.
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Minaprine.
OxycodoneThe risk or severity of adverse effects can be increased when Minaprine is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Minaprine.
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Minaprine.
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Minaprine.
PanobinostatThe metabolism of Minaprine can be decreased when combined with Panobinostat.
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Minaprine.
PargylineMinaprine may increase the hypotensive activities of Pargyline.
ParoxetineMinaprine may increase the serotonergic activities of Paroxetine.
ParoxetineThe metabolism of Minaprine can be decreased when combined with Paroxetine.
PasireotideMinaprine may increase the hypoglycemic activities of Pasireotide.
Peginterferon alfa-2bThe serum concentration of Minaprine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololMinaprine may increase the bradycardic activities of Penbutolol.
PentamidineMinaprine may increase the hypoglycemic activities of Pentamidine.
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Minaprine.
PergolideThe metabolism of Pergolide can be decreased when combined with Minaprine.
PerindoprilMinaprine may increase the hypotensive activities of Perindopril.
PethidineMinaprine may increase the serotonergic activities of Pethidine.
PhenoxybenzamineMinaprine may increase the hypotensive activities of Phenoxybenzamine.
PhentermineMinaprine may increase the hypertensive activities of Phentermine.
PhentolamineMinaprine may increase the hypotensive activities of Phentolamine.
PhenylephrineMinaprine may increase the hypertensive activities of Phenylephrine.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Minaprine is combined with Phenylpropanolamine.
PholcodinePholcodine may increase the serotonergic activities of Minaprine.
PilocarpineThe risk or severity of adverse effects can be increased when Minaprine is combined with Pilocarpine.
PinacidilMinaprine may increase the hypotensive activities of Pinacidil.
PindololMinaprine may increase the bradycardic activities of Pindolol.
PioglitazoneMinaprine may increase the hypoglycemic activities of Pioglitazone.
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Minaprine.
PirbuterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Pirbuterol.
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Minaprine.
PizotifenMinaprine may increase the anticholinergic activities of Pizotifen.
PolythiazideMinaprine may increase the hypotensive activities of Polythiazide.
PractololMinaprine may increase the bradycardic activities of Practolol.
PramlintideMinaprine may increase the hypoglycemic activities of Pramlintide.
PrazosinMinaprine may increase the hypotensive activities of Prazosin.
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Minaprine.
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Minaprine.
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Minaprine.
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Minaprine.
ProcaterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Procaterol.
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Minaprine.
PromazineThe metabolism of Minaprine can be decreased when combined with Promazine.
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Minaprine.
PropranololMinaprine may increase the bradycardic activities of Propranolol.
ProtriptylineMinaprine may increase the serotonergic activities of Protriptyline.
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Minaprine.
QuinaprilMinaprine may increase the hypotensive activities of Quinapril.
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Minaprine.
QuinidineThe metabolism of Minaprine can be decreased when combined with Quinidine.
QuinineMinaprine may increase the hypoglycemic activities of Quinine.
QuinineThe metabolism of Minaprine can be decreased when combined with Quinine.
RamiprilMinaprine may increase the hypotensive activities of Ramipril.
RanolazineThe metabolism of Minaprine can be decreased when combined with Ranolazine.
RapacuroniumMinaprine may decrease the neuromuscular blocking activities of Rapacuronium.
RemikirenMinaprine may increase the hypotensive activities of Remikiren.
RepaglinideMinaprine may increase the hypoglycemic activities of Repaglinide.
RescinnamineMinaprine may increase the hypotensive activities of Rescinnamine.
ReserpineMinaprine may increase the hypotensive activities of Reserpine.
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Minaprine.
RiociguatMinaprine may increase the hypotensive activities of Riociguat.
RitodrineThe risk or severity of adverse effects can be increased when Minaprine is combined with Ritodrine.
RitonavirThe metabolism of Minaprine can be decreased when combined with Ritonavir.
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Minaprine.
RolapitantThe metabolism of Minaprine can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Minaprine can be decreased when combined with Ropinirole.
RosiglitazoneMinaprine may increase the hypoglycemic activities of Rosiglitazone.
SalbutamolThe risk or severity of adverse effects can be increased when Minaprine is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Salmeterol.
SaprisartanMinaprine may increase the hypotensive activities of Saprisartan.
SaxagliptinMinaprine may increase the hypoglycemic activities of Saxagliptin.
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Minaprine.
Scopolamine butylbromideThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Minaprine.
SelexipagMinaprine may increase the hypotensive activities of Selexipag.
SertralineMinaprine may increase the serotonergic activities of Sertraline.
SertralineThe metabolism of Minaprine can be decreased when combined with Sertraline.
SitagliptinMinaprine may increase the hypoglycemic activities of Sitagliptin.
SitaxentanMinaprine may increase the hypotensive activities of Sitaxentan.
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Minaprine.
SotalolMinaprine may increase the bradycardic activities of Sotalol.
SpiraprilMinaprine may increase the hypotensive activities of Spirapril.
StiripentolThe metabolism of Minaprine can be decreased when combined with Stiripentol.
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Minaprine.
SulfadiazineMinaprine may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleMinaprine may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleMinaprine may increase the hypoglycemic activities of Sulfisoxazole.
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Minaprine.
SunitinibMinaprine may increase the hypoglycemic activities of Sunitinib.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Minaprine.
TelmisartanMinaprine may increase the hypotensive activities of Telmisartan.
TemocaprilMinaprine may increase the hypotensive activities of Temocapril.
TerbinafineThe metabolism of Minaprine can be decreased when combined with Terbinafine.
TerbutalineThe risk or severity of adverse effects can be increased when Minaprine is combined with Terbutaline.
TerlipressinMinaprine may increase the hypotensive activities of Terlipressin.
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Minaprine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Minaprine.
TetryzolineMinaprine may increase the hypertensive activities of Tetryzoline.
ThioridazineThe metabolism of Minaprine can be decreased when combined with Thioridazine.
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Minaprine.
TianeptineMinaprine may increase the serotonergic activities of Tianeptine.
TiboloneMinaprine may increase the hypotensive activities of Tibolone.
TiclopidineThe metabolism of Minaprine can be decreased when combined with Ticlopidine.
TicrynafenMinaprine may increase the hypotensive activities of Ticrynafen.
TimololMinaprine may increase the bradycardic activities of Timolol.
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Minaprine.
TipranavirThe metabolism of Minaprine can be decreased when combined with Tipranavir.
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Minaprine.
TolazamideMinaprine may increase the hypoglycemic activities of Tolazamide.
TolazolineMinaprine may increase the hypotensive activities of Tolazoline.
TolbutamideMinaprine may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Minaprine.
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Minaprine.
TorasemideMinaprine may increase the hypotensive activities of Torasemide.
TramadolTramadol may increase the neuroexcitatory activities of Minaprine.
TrandolaprilMinaprine may increase the hypotensive activities of Trandolapril.
TranylcypromineThe metabolism of Minaprine can be decreased when combined with Tranylcypromine.
TravoprostMinaprine may increase the hypotensive activities of Travoprost.
TrazodoneMinaprine may increase the serotonergic activities of Trazodone.
TreprostinilMinaprine may increase the hypotensive activities of Treprostinil.
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Minaprine.
TrichlormethiazideMinaprine may increase the hypotensive activities of Trichlormethiazide.
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Minaprine.
TrimazosinMinaprine may increase the hypotensive activities of Trimazosin.
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Minaprine.
TrimipramineMinaprine may increase the serotonergic activities of Trimipramine.
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Minaprine.
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Minaprine.
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Minaprine.
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with Minaprine.
UnoprostoneMinaprine may increase the hypotensive activities of Unoprostone.
ValsartanMinaprine may increase the hypotensive activities of Valsartan.
VareniclineThe risk or severity of adverse effects can be increased when Minaprine is combined with Varenicline.
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Minaprine.
VenlafaxineThe metabolism of Minaprine can be decreased when combined with Venlafaxine.
VenlafaxineMinaprine may increase the serotonergic activities of Venlafaxine.
VilanterolThe risk or severity of adverse effects can be increased when Minaprine is combined with Vilanterol.
VilazodoneMinaprine may increase the serotonergic activities of Vilazodone.
VortioxetineMinaprine may increase the serotonergic activities of Vortioxetine.
XylometazolineMinaprine may increase the hypotensive activities of Xylometazoline.
ZimelidineMinaprine may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe metabolism of Minaprine can be decreased when combined with Ziprasidone.
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Minaprine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Kan JP, Mouget-Goniot C, Worms P, Biziere K: Effect of the antidepressant minaprine on both forms of monoamine oxidase in the rat. Biochem Pharmacol. 1986 Mar 15;35(6):973-8. [PubMed:3954800 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Kodama K, Shibata S, Ueki S: Protective effect of minaprine against the abnormal changes of 2-deoxyglucose uptake by rat hippocampal slices induced by hypoxia/hypoglycemia. Jpn J Pharmacol. 1992 Sep;60(1):33-8. [PubMed:1361012 ]
  4. Muramatsu M, Tamaki-Ohashi J, Usuki C, Araki H, Chaki S, Aihara H: 5-HT2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat brain striatal slices. Eur J Pharmacol. 1988 Aug 9;153(1):89-95. [PubMed:2975224 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Kodama K, Shibata S, Ueki S: Protective effect of minaprine against the abnormal changes of 2-deoxyglucose uptake by rat hippocampal slices induced by hypoxia/hypoglycemia. Jpn J Pharmacol. 1992 Sep;60(1):33-8. [PubMed:1361012 ]
  2. Nabeshima T, Kawashima K, Kameyama T: Effect of minaprine on cycloheximide-induced amnesia in mice. Eur J Pharmacol. 1989 Oct 10;169(2-3):249-57. [PubMed:2530096 ]
  3. Muramatsu M, Tamaki-Ohashi J, Usuki C, Araki H, Chaki S, Aihara H: 5-HT2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat brain striatal slices. Eur J Pharmacol. 1988 Aug 9;153(1):89-95. [PubMed:2975224 ]
  4. Biziere K, Worms P, Kan JP, Mandel P, Garattini S, Roncucci R: Minaprine, a new drug with antidepressant properties. Drugs Exp Clin Res. 1985;11(12):831-40. [PubMed:3836113 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Kodama K, Shibata S, Ueki S: Protective effect of minaprine against the abnormal changes of 2-deoxyglucose uptake by rat hippocampal slices induced by hypoxia/hypoglycemia. Jpn J Pharmacol. 1992 Sep;60(1):33-8. [PubMed:1361012 ]
  4. Muramatsu M, Tamaki-Ohashi J, Usuki C, Araki H, Chaki S, Aihara H: 5-HT2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat brain striatal slices. Eur J Pharmacol. 1988 Aug 9;153(1):89-95. [PubMed:2975224 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine hydrolase activity
Specific Function:
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name:
ACHE
Uniprot ID:
P22303
Molecular Weight:
67795.525 Da
References
  1. Duarte CD, Barreiro EJ, Fraga CA: Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19. [PubMed:18045214 ]
  2. Contreras JM, Rival YM, Chayer S, Bourguignon JJ, Wermuth CG: Aminopyridazines as acetylcholinesterase inhibitors. J Med Chem. 1999 Feb 25;42(4):730-41. [PubMed:10052979 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Duarte CD, Barreiro EJ, Fraga CA: Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19. [PubMed:18045214 ]
  2. Worms P, Kan JP, Steinberg R, Terranova JP, Perio A, Biziere K: Cholinomimetic activities of minaprine. Naunyn Schmiedebergs Arch Pharmacol. 1989 Oct;340(4):411-8. [PubMed:2586634 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23